Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer

Doxorubicin and Anti-PD-L1 Antibody Conjugated Gold Nanoparticles for Colorectal Cancer Photochemotherapy

(2019) Fakhrossadat Emami et al.   MOLECULAR PHARMACEUTICS

PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma

(2019) Yui Hirata-Nozaki et al.   Journal of Translational Medicine

Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma

(2019) Shohei Harabuchi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

High Vimentin Expression Predicts a Poor Prognosis and Progression in Colorectal Cancer: A Study with Meta-Analysis and TCGA Database

(2018) Le Du et al.   Biomed Research International

Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma

(2018) Kenzo Ohara et al.   OncoImmunology

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

UniProt: the universal protein knowledgebase

(2016)   NUCLEIC ACIDS RESEARCH

Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses

(2016) Takumi Kumai et al.   Cancer Immunology Research

High Vimentin Expression Associated with Lymph Node Metastasis and Predicated a Poor Prognosis in Oral Squamous Cell Carcinoma

(2016) Shuli Liu et al.   Scientific Reports

Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4+ T-Cell-Mediated Antitumor Immunity

(2015) V. A. Brentville et al.   CANCER RESEARCH

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma

(2015) Takumi Kumai et al.   Scientific Reports

Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53

(2014) Takumi Kumai et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy

(2013) T Kumai et al.   BRITISH JOURNAL OF CANCER

Increased expression of Slug and Vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer

(2013) Yuji Toiyama et al.   CARCINOGENESIS

Curcumin Suppresses Doxorubicin-Induced Epithelial–Mesenchymal Transition via the Inhibition of TGF-β and PI3K/AKT Signaling Pathways in Triple-Negative Breast Cancer Cells

(2013) Wei-Chih Chen et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Cancer Peptide Vaccine Therapy Developed from Oncoantigens Identified through Genome-wide Expression Profile Analysis for Bladder Cancer

(2012) W. Obara et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths

(2012) Ann G. Zauber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer

(2011) Satoshi Hayashi et al.   Journal of Translational Medicine

Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol

(2010) Marissa Albert et al.   CANCER

Tumor-reactive CD4+T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

(2010) Sergio A. Quezada et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Vimentin is a novel AKT1 target mediating motility and invasion

(2010) Q-S Zhu et al.   ONCOGENE

Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy

(2009) F. R. Depontieu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA